C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/18 (2006.01) A61K 49/00 (2006.01) C07K 14/47 (2006.01) G01N 33/543 (2006.01) G01N 33/566 (2006.01) G01N 33/577 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2115900
Abstract This invention describes a series of assays useful in evaluating the efficacy of agents which inhibit the neurotoxic effects of .beta.-amyloid peptide. These assays employ .beta.-amyloid peptide which is in a predominantly .beta.- sheet conformation. This invention also encompasses antibodies having a specificity for .beta.-amyloid peptide which is predominantly in a .beta.-sheet conformation as well as pharmaceutic formulations containing these antibodies. These antibodies show poor reactivity with .beta.-amyloid peptide which has a great deal of random coil or .alpha.-helix secondary structure.
Becker Gerald W.
Brems David N.
Chaney Michael O.
May Patrick
Rydel Russell E.
Athena Neurosciences Inc.
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Pharmaceutical screens and antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical screens and antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical screens and antibodies will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1941704